Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: New Immunotherapy Strategies in the NCCN Guidelines
NCCN Annual Conference 2019
Matthew A. Gubens, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent updates to the NCCN Guidelines in non–small cell lung cancer, including the use of pembrolizumab as a single agent or in combination based on PD-L1 status, treatment selection in squamous and nonsquamous patients, and how mutational status affects treatment strategy.
Michelle B. Riba, MD, of the University of Michigan Rogel Cancer Center, discusses the prevalence of distress in patients with cancer, the need for a quick and simple screening method to identify patients with distress, and strategies for improving integration of psychosocial care into routine cancer care.
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses major findings over the past 12 months in kidney cancer, including combination immunotherapies and trends in surgical oncology.
Neil P. Shah, MD, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the feasibility of discontinuing tyrosine kinase inhibitor therapy in select patients with chronic phase chronic myeloid leukemia outside of clinical trials.
William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses evidence-based first-line treatment options for patients with advanced hormone receptor–positive, HER2-negative breast cancer and toxicities associated with the various therapeutic options.
Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative disease.
